Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B

被引:34
|
作者
Han, E. [1 ]
Lee, Y. -H. [2 ,3 ]
Kim, B. K. [2 ,4 ]
Park, J. Y. [2 ,4 ]
Kim, D. Y. [2 ,4 ]
Ahn, S. H. [2 ,4 ]
Lee, B. -W. [2 ,3 ]
Kang, E. S. [2 ,3 ]
Cha, B. -S. [2 ,3 ]
Han, K. -H. [2 ,4 ]
Kim, S. U. [2 ,4 ]
机构
[1] Keimyung Univ, Sch Med, Dept Internal Med, Daegu, South Korea
[2] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Inst Endocrine Res, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Inst Gastroenterol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
SURVEYS KNHANES 2008-2011; INSULIN-RESISTANCE; HEPATOCELLULAR-CARCINOMA; FOLLOW-UP; DISEASE; CIRRHOSIS; DIAGNOSIS; MANAGEMENT; NUTRITION; STEATOHEPATITIS;
D O I
10.1111/apt.14843
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Methods: Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m(2)]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cutoffs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index >= 2.67. Results: Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05). Conclusions: Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.
引用
收藏
页码:300 / 312
页数:13
相关论文
共 50 条
  • [41] Circulating microRNAs associated with liver fibrosis in chronic hepatitis C patients
    Cabral, B. C. A.
    Hoffmann, L.
    Bottaro, T.
    Costa, P. F.
    Ramos, A. L. A.
    Coelho, H. S. M.
    Villela-Nogueira, C. A.
    Urmenyi, T. P.
    Faffe, D. S.
    Silva, R.
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2020, 24
  • [42] Non-invasive assessment of liver fibrosis in chronic hepatitis B
    Branchi, Federica
    Conti, Clara Benedetta
    Baccarin, Alessandra
    Lampertico, Pietro
    Conte, Dario
    Fraquelli, Mirella
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (40) : 14568 - 14580
  • [43] Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients
    Li, Xu
    Gao, Yang
    Xu, Hongqin
    Hou, Jie
    Gao, Pujun
    SCIENTIFIC REPORTS, 2017, 7
  • [44] Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
    Kim, Beom Kyung
    Kim, Hyon Suk
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Chon, Chae Yoon
    Park, Young Nyun
    Han, Kwang-Hyub
    Kim, Seung Up
    PLOS ONE, 2012, 7 (07):
  • [45] Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B
    Wu, Sheng-di
    Ni, Yan-jun
    Liu, Li-li
    Li, Hai
    Lu, Lun-gen
    Wang, Ji-Yao
    HEPATOLOGY INTERNATIONAL, 2012, 6 (01) : 360 - 368
  • [46] Serum liver fibrosis markers discriminate significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase
    Liao, Yuan
    Gong, Jiao
    Zhou, Wenying
    Dong, Huimin
    Liang, Jiayin
    Luo, Minqi
    Hu, Bo
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (04) : 642 - 649
  • [47] Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection
    Mak, Lung-Yi
    Hui, Rex Wan-Hin
    Fung, James
    Liu, Fen
    Wong, Danny Ka-Ho
    Li, Bofei
    Cheung, Ka-Shing
    Yuen, Man-Fung
    Seto, Wai-Kay
    HEPATOLOGY INTERNATIONAL, 2021, 15 (04) : 901 - 911
  • [48] Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B
    Park, Mi Sung
    Kim, Beom Kyung
    Cheong, Jae Yoeun
    Kim, Dong Joon
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    Chon, Chae Yoon
    Kim, Seung Up
    PLOS ONE, 2013, 8 (02):
  • [49] Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B
    Marcellin, Patrick
    Ziol, Marianne
    Bedossa, Pierre
    Douvin, Catherine
    Poupon, Raoul
    de Ledinghen, Victor
    Beaugrand, Michel
    LIVER INTERNATIONAL, 2009, 29 (02) : 242 - 247
  • [50] Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease
    Chun, Ho Soo
    Kim, Mi Na
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Seung Up
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2021, 12 (05) : 1168 - 1178